What is Plexium?
Plexium is at the forefront of developing small molecules that modulate E3 ligases, a critical mechanism for treating complex diseases such as cancer and neurodegenerative disorders. The company's proprietary DELPhe (DNA-Encoded Library phenotypic screening) platform is a key differentiator. This advanced screening technology leverages droplet and microwell confinement to miniaturize cell-based assays, enabling high-content readouts at exceptionally low costs and high throughput. This efficiency is crucial for accelerating the identification of promising drug candidates in a highly competitive pharmaceutical landscape.
How much funding has Plexium raised?
Plexium has raised a total of $225.1M across 4 funding rounds:
Series A
$28M
Other Financing Round
$35M
Other Financing Round
$102M
Private Equity
$60.1M
Series A (2019): $28M with participation from The Column Group, DCVC Bio, M Ventures, Neotribe Ventures, and CRV
Other Financing Round (2021): $35M led by PIVOTAL BIOVENTURE PARTNERS LLC, Lux Capital, DCVC Bio, and The Column Group
Other Financing Round (2022): $102M supported by Softbank Vision Fund 2, TCG X, BVF Partners, Surveyor Capital, Pappas Capital, L.P., and RA Capital Management
Private Equity (2025): $60.1M, investors not publicly disclosed
Key Investors in Plexium
The Column Group
The Column Group (TCG) is a venture ecosystem focused on advancing scientific innovation in the life sciences sector, known for supporting early-stage technology platforms and later-stage programs in biotechnology.
DCVC Bio
DCVC Bio is a deep tech venture capital firm that invests in entrepreneurs tackling challenging problems, with a focus on leveraging artificial intelligence in sectors including biotechnology.
M Ventures
M Ventures is the strategic, corporate venture capital arm of Merck, investing globally in innovative technologies and products with the potential to impact core business areas, with a significant focus on early-stage investing.
What's next for Plexium?
With this latest round of major strategic investment, Plexium is poised to accelerate its research and development pipeline. The significant capital infusion, part of its enterprise-level funding strategy, will likely be directed towards advancing its lead programs through preclinical and clinical development, expanding its platform capabilities, and potentially forging strategic partnerships. The company's focus on E3 ligase modulation places it in a rapidly growing area of targeted therapeutics, suggesting a future trajectory aimed at bringing novel treatments to patients suffering from debilitating diseases.
See full Plexium company page
